H07 — Intestinal ER-antagonism thesis

Status: Retracted. The card promoted a disclosed n=1 temporal association into a general clomiphene effect, then privileged an intestinal mechanism that had not been demonstrated.

Retracted claim

Clomiphene-associated serum-urate elevation in gout-prone men is mediated primarily by intestinal estrogen-receptor antagonism that reduces ABCG2-dependent urate export.

Why the claim was withdrawn

1. A multilingual literature scan found no prospective study, cohort, or case report showing that clomiphene initiation raises serum urate or causes first-onset gout. The only direct PubMed clomiphene-plus-gout result studied hormone responses in people who already had gout (PMID 3918542).
2. The observation that motivated H07 was a single longitudinal case, not a published clinical observation. It can generate a hypothesis but cannot establish direction, frequency, or mechanism in other people.
3. Human androgen manipulation can change serum urate, which supports Mechanistic Extrapolation. It does not establish that clomiphene has the same net effect because clomiphene changes testosterone, estradiol, SHBG, and estrogen-receptor signaling together.
4. No direct evidence showed that clomiphene acts as a functionally important antagonist in human enterocytes at relevant exposure. Evidence against direct androgen-receptor repression of intestinal ABCG2 does not identify intestinal ER antagonism as the replacement mechanism.

The dose–hormone–urate signal is now tested without assuming a compartment or mechanism in H10. Intestinal clomiphene/enclomiphene/zuclomiphene effects remain a separate cell-biology question.

Retraction record

Date	Outcome	Basis
2026-07-17	Retracted	Founding n=1 signal had been generalized as an observed drug effect; direct clomiphene–urate evidence was not found, and the proposed intestinal mechanism was untested.